Xuyong Wei
Overview
Explore the profile of Xuyong Wei including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
109
Citations
1021
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
41.
Qiu N, Zhang Z, Wei X, Xu C, Jia X, Wang K, et al.
Nano Lett
. 2023 Jul;
23(17):7859-7868.
PMID: 37433066
Peritoneal metastasis is very common in gastrointestinal, reproductive, and genitourinary tract cancers in late stages or postsurgery, causing poor prognosis, so effective and nontoxic prophylactic strategies against peritoneal metastasis are...
42.
Yang M, Wei X, Khan A, Wei Q, Wang R, Pan B, et al.
J Clin Transl Hepatol
. 2023 Jul;
11(4):827-838.
PMID: 37408815
Background And Aims: Liver transplantation (LT) using ABO-incompatible (ABOi) grafts can extend the donor pool to a certain extent and hence reduce the waiting time for transplantation. However, concerns of...
43.
Song Y, Xiang Z, Lu Z, Su R, Shu W, Sui M, et al.
J Cancer Res Clin Oncol
. 2023 Jun;
149(13):11319-11332.
PMID: 37380815
Purpose: Given that prognosis of hepatocellular carcinoma (HCC) differs dramatically, it is imperative to uncover effective and available prognostic biomarker(s). The intratumor microbiome plays a significant role in the response...
44.
Liu L, Liu J, Li P, Luo J, Qin R, Peng Q, et al.
J Exp Clin Cancer Res
. 2023 Jun;
42(1):152.
PMID: 37353792
Immune checkpoint blockade (ICB) treatment of hepatocellular carcinoma (HCC) patients with hepatitis B virus (HBV) infection may activate viral-specific T cells to attack HBV infected hepatocytes and thus induce immune-related...
45.
Zhang Z, Xu L, Qiu X, Yang X, Lian Z, Wei X, et al.
J Zhejiang Univ Sci B
. 2023 Jun;
24(6):485-495.
PMID: 37309040
Tacrolimus (TAC), also called FK506, is one of the classical immunosuppressants to prevent allograft rejection after liver transplantation. However, it has been proved to be associated with post-transplant hyperlipemia. The...
46.
Lu X, Guo H, Wei X, Lu D, Shu W, Song Y, et al.
Int J Nanomedicine
. 2023 Jun;
18:2873-2890.
PMID: 37283714
With the improvement of the average life expectancy and increasing incidence of obesity, the burden of liver disease is increasing. Liver disease is a serious threat to human health. Currently,...
47.
Li H, Lin Z, Zhuo J, Yang M, Shen W, Hu Z, et al.
Chin J Cancer Res
. 2023 Mar;
35(1):66-80.
PMID: 36910852
Objective: Lung metastasis is a common and fatal complication of liver transplantation for hepatocellular carcinoma (HCC). The precise prediction of post-transplant lung metastasis in the early phase is of great...
48.
Lin Z, Li H, He C, Yang M, Chen H, Yang X, et al.
Front Oncol
. 2023 Feb;
13:1072775.
PMID: 36845695
Background: Early diagnosis for α-fetoprotein (AFP) negative hepatocellular carcinoma (HCC) remains a critical problem. Metabolomics is prevalently involved in the identification of novel biomarkers. This study aims to identify new...
49.
Li J, Wang J, Liu Z, Guo H, Wei X, Wei Q, et al.
J Cancer Res Ther
. 2023 Jan;
18(7):1919-1925.
PMID: 36647950
Objective: Revealing microfibrillar-associated protein 4 (MFAP4)'s function and its clinical significance in hepatocellular carcinoma (HCC). Methods: Quantitative real-time polymerase chain reaction (qRT-PCR) and western blotting were used to evaluate MFAP4...
50.
Wang S, Wang R, Xu N, Wei X, Yang Y, Lian Z, et al.
Hepatology
. 2023 Jan;
78(4):1064-1078.
PMID: 36626623
Background And Aims: HCC is a malignant disease. Compared with tyrosine kinase inhibitors (the classical therapy), immune checkpoint inhibitors are more effective in the treatment of HCC, despite their limited...